ArticleScientific reports2021
Clinical outcomes of combined Preserflo Microshunt implantation and cataract surgery in open-angle glaucoma patients.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Minimally Invasive Bleb Surgery for Glaucoma: A Health Technology Assessment.Ontario health technology assessment series · 2024Pooled it
- Standalone versus combined preserflo MicroShunt surgery: A two-year controlled cohort study.Eye (London, England) · 2026Article
- Comparison of surgically induced astigmatism following PreserFlo MicroShunt implantation versus trabeculectomy in Japanese patients with glaucoma.Japanese journal of ophthalmology · 2026Article
- Functional assessment of the Preserflo MicroShunt implant in pigmentary glaucoma: 2 years follow-up.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Observational
- Efficacy and Safety of the PreserfloJournal of clinical medicine · 2026Article
- Long-term outcomes after phacoemulsification and trabeculectomy in uncontrolled glaucoma and cataract in staged versus combined approaches: a single-center observational study.BMC ophthalmology · 2026Observational
- Management practices and surgical techniques for ab externo less invasive glaucoma surgery: a literature review and expert recommendations.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Review
- PRESERFLO™ MicroShunt as a treatment option for highly increased intraocular pressure in primary open angle glaucoma and pseudoexfoliation glaucoma.Eye (London, England) · 2025Article
- Factors Affecting Bleb Morphology and Postoperative Intraocular Pressure in Inferotemporal PreserFlo MicroShunt Implantation.Translational vision science & technology · 2025Article
- Preserflo-MicroShunt: Postoperative Effects on Endothelial Cell Density and Corneal Thickness.Biomedicines · 2025Article
- Xen 63 versus Preserflo MicroShunt implant in patients with primary open-angle glaucoma.Scientific reports · 2025Article
- Preserflo MicroShunt Implantation: A Narrative Review of Its Standalone Benefits vs. Combined Use with Phacoemulsification in Managing Open-Angle Glaucoma.Ophthalmology and therapy · 2025Review
- Transient hyphema associated with PRESERFLOScientific reports · 2024Article
- Additional Guidance on the Use of the PRESERFLO™ MicroShunt in the Treatment of Glaucoma: Insights from a Second Delphi Consensus Panel.Ophthalmology and therapy · 2024Article
- Long-Term Outcomes of the PRESERFLO MicroShunt Implant in a Heterogeneous Glaucoma Cohort.Journal of clinical medicine · 2023Article
- Efficacy of the PRESERFLO MicroShunt and a Meta-Analysis of the Literature.Journal of clinical medicine · 2022Article
- Minimally Invasive Glaucoma Surgery: Safety of Individual Devices.Journal of clinical medicine · 2022Review
- Expert Consensus on the Use of the PRESERFLO™ MicroShunt Device in the Treatment of Glaucoma: A Modified Delphi Panel.Ophthalmology and therapy · 2022Article
- PreserFloVision (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To assess the effectiveness and safety of the Preserflo Microshunt (PMS) implantation combined with cataract surgery in open-angle glaucoma (OAG) patients. Retrospective, open-label study conducted on insufficiently controlled OAG patients, who underwent a PMS implant procedure with mitomycin-C 0.2%, either alone or in combination with cataract surgery, and were followed for at least 12 months. Success was defined as an intraocular pressure (IOP) ≤ 18 mmHg and a reduction of at least 20% without (complete) or with (qualified) hypotensive medication. Fifty-eight eyes were included in the study, 35 eyes underwent PMS alone and 23 underwent PMS + Phaco. In the overall study sample, mean IOP was significantly lowered from 21.5 ± 3.3 mmHg at baseline to 14.6 ± 3.5 mmHg at month 12 (p < 0.0001). The IOP was significantly reduced in both groups; p < 0.0001 each, respectively. Ocular hypotensive medication was significantly reduced (p < 0.0001) in both groups. No significant differences were observed in IOP lowering or medication reduction between groups. At month 12, 62.1% eyes were considered as complete success and 82.8% eyes as qualified success. The most common adverse events were device close-to-endothelium, conjunctival fibrosis, and wound leakage. PMS, either alone or in combination with phacoemulsification, may be considered as a valuable option for treating OAG patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.